Abstract Supplement ventilator-dependent patients and one for spontaneously breathing patients. Correction factors for gender, the presence of additional trauma, and obesity are indicated on the graphical calculators.
INTRODUCTION:
The aim of this study was to assess the efficacy and safety of topical timolol 0.5% drops in healing chronic refractory ulcers of various etiologies in a large patient cohort.
METHODS:
From January to June 2016 we recruited 82 consecutive patients affected by nonhealing loss of substance associated to diverse etiologies (venous, diabetic, post-surgery, postradiation, pressure, mistreated burns). All lesions were chronic, had been present for at least 3 months. All patients had been treated with the appropriate standard of care with no therapeutic response. All patients were > 18 year old. Each patient was treated with topical timolol drops 0.5% (1 drop every 2 cm of wound area\day for 6 weeks), then covered with polyurethane film and 3 layers of dressings. Objective assessment was carried out through wound area tracing at baseline, at 6 weeks of therapy, and at the 6 month followup. 10 patients underwent assessment of timolol plasma levels concentration at 6 weeks. Adverse events were recorded at each time point.
RESULTS:
A statistical significant improvement in % of area reduction (up to 98.75%) and mean size was noted in every group except diabetic and pressure ulcers. The mean area reduction in % persisted or improved at 6 months in all groups, except diabetic and pressure ulcers, which tended to recur. VAS scale documented good to excellent patient satisfaction in every group except the diabetic and pressure ones. 6 patients developed contact dermatitis. No patient presented cardiologic parameters abnormalities; timolol plasma levels were undetectable in the 10 assessed patients.
CONCLUSION:
Few reports have documented the efficacy of topical beta-blockers in chronic and treatment-refractory ulcers. [1] [2] [3] [4] At present there is a noticeable lack of randomized controlled evidence in the international literature. To date, this represents the most comprehensive experience in terms of patients numbers and type of loss of substance documenting the use of topical betablockers in wound healing. We obtained satisfactory results in every group with the exception of diabetic and pressure ulcers, which responded poorly at 6 weeks and had a tendency to recur. Adverse effects were mild to moderate and required no dose adjustment, with the exception of 1 patient that was forced to give up treatment. Specific dosage and application protocols need to be optimized by further observations.
